Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pharmacokinetics of Triferic (Ferric Pyrophosphate Citrate) Administered Intravenously to Healthy Adult Volunteers (RMFPC-12)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02636049
Recruitment Status : Completed
First Posted : December 21, 2015
Results First Posted : February 1, 2019
Last Update Posted : August 20, 2019
Sponsor:
Information provided by (Responsible Party):
Rockwell Medical Technologies, Inc.

Brief Summary:
This is a Phase 1, open-label, three-period sequential dosing study being conducted to determine the pharmacokinetics of Triferic iron administered intravenously (IV) to healthy adults.

Condition or disease Intervention/treatment Phase
End Stage Renal Disease Drug: Triferic Phase 1

Detailed Description:
This is a Phase 1, open-label, three-period sequential dosing study being conducted primarily to determine the pharmacokinetics of Triferic iron administered intravenously to healthy adults.. Participation will be up to 5 weeks total duration including Screening, Baseline, Treatment Period, and Follow-up. Following Screening, subjects will be admitted to the clinic on Day -1, prior to Baseline (Day 1). During the Treatment Period, subjects will receive two doses of Triferic. Each subject will receive a single 6-mg dose of Triferic administered IV over 3 hours (hr) on one day (Day 2), and a single 35-µg/kg dose of Triferic administered IV push the following day (Day 3). On Day 4, subjects will be discharged from the clinic and will return approximately one week later for their final Follow-up visit.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 12 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Pharmacokinetics of Triferic (Ferric Pyrophosphate Citrate) Administered Intravenously to Healthy Adult Volunteers
Study Start Date : October 2015
Actual Primary Completion Date : October 2015
Actual Study Completion Date : October 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Iron

Arm Intervention/treatment
Experimental: Treatment Period: 6 mg Triferic IV over 3 hours
Each subject will receive a single 6 mg dose of Triferic administered as a continuous intravenous infusion over 3 hours on Day 2. The Triferic IV dosing solution will have been prepared by diluting Triferic from ampules (5.44 mg/mL) in an appropriate amount of D5W to a concentration of 0.020 mg/mL. Administration of 300 mL IV at 100 mL/hr for 3 hours results in delivery of 6 mg of Triferic iron.
Drug: Triferic
Triferic is supplied as sterile 5 mL ampules containing 5.44 mg/mL of iron in water for injection. Each 5 mL ampule contains 27.2 mg of Triferic iron.
Other Names:
  • ferric pyrophosphate citrate
  • FPC

Experimental: Treatment Period: 35 micrograms/kg IV push
Each subject will receive Triferic as 35 µg/kg body weight IV push over 30-60 seconds on Day 3. The Triferic IV push dosing solution will have been prepared by diluting Triferic from ampules (5.44 mg/mL) in an appropriate amount of D5W to a concentration of 35 µg Triferic iron/kg body weight per subject in 4.5 mL.
Drug: Triferic
Triferic is supplied as sterile 5 mL ampules containing 5.44 mg/mL of iron in water for injection. Each 5 mL ampule contains 27.2 mg of Triferic iron.
Other Names:
  • ferric pyrophosphate citrate
  • FPC




Primary Outcome Measures :
  1. Pharmacokinetics of Triferic Iron Administered IV to Healthy Adults: Maximum Drug Concentration (Cmax) of Total Serum Iron [ Time Frame: 16 hours ]
    Blood samples will be drawn at time = 0, 1, 2, 3, 3.5, 4, 4.5, 5, 6, 8, 12, and 16 hours after the start of Triferic administration on study Day 2 (IV infusion of 6 mg Triferic over 3 hours) and Day 3 (35 microgram/kg IV dose of Triferic given over 30 - 60 seconds) in order to determine the Peak Serum Concentration, corrected (Cmax) of total serum iron.

  2. Pharmacokinetics of Triferic Iron Administered IV to Healthy Adults: Area Under the Serum Iron Concentration Time Curve From Time Zero to the Time of Last Quantified Concentration (AUC(Last)) of Total Serum Iron [ Time Frame: 16 hours ]
    Blood samples will be drawn at time = 0, 1, 2, 3, 3.5, 4, 4.5, 5, 6, 8, 12, and 16 hours after the start of Triferic administration on study Day 2 (IV infusion of 6 mg Triferic over 3 hours) and study day 3 (35 microgram/kg IV Triferic dose administered in 30 - 60 seconds) in order to determine the AUC(last) of total serum iron.


Secondary Outcome Measures :
  1. Incidence of Treatment Emergent Adverse Events [ Time Frame: 10 - 14 days ]
    The number of patients that experienced treatment emergent adverse events will be quantified.

  2. Incidence of Treatment Emergent Serious Adverse Events [ Time Frame: 10 - 14 days ]
    The number of patients that experienced treatment emergent serious adverse events (TESEAs) will be quantified.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria: Subjects must meet all of the following criteria to be eligible for inclusion in the study:

  1. The subject must be able to provide informed consent and have personally signed and dated the study written informed consent document before completing any study-related procedures.
  2. The subject must be 18-65 years of age inclusive at the time of consent.
  3. The subject must have a transferrin saturation (TSAT) of 15-50% during Screening.
  4. The subject must agree to discontinue all iron preparations for 14 days prior to Baseline.
  5. If the subject is female, she must be premenopausal, non-pregnant and non-lactating, and be at least 90 days post-partum (if applicable) at Screening. Women of childbearing potential must be willing to use appropriate birth control during the entire duration of the study.
  6. The subject must be willing and able to comply with all study procedures and restrictions.
  7. The subject must have no clinically-significant abnormal findings on medical history, vital signs, physical examination, or clinical laboratory results during Screening.
  8. The subject must have a body mass index (BMI) of ≤32.0 kg/m2 at Screening and weigh >60.0 kg.

Exclusion Criteria:

A subject will not be eligible for inclusion in the study if any of the following criteria apply:

  1. The subject has a hemoglobin (Hgb) concentration <13.0 g/dL for men or <12 g/dL for women during Screening.
  2. The subject has a total iron binding capacity (TIBC) <250 µg/dL during Screening.
  3. The subject has had administration of IV or oral iron supplements (including multivitamins with iron) within 14 days prior to Baseline.
  4. Subject has concurrent or recurrent disease (e.g., cardiovascular, renal, hepatic, gastrointestinal, malignant, etc.) that could affect the action or disposition of the investigational product utilized in this study, or could affect clinical or laboratory assessments.
  5. Subject has a C-reactive protein level (CRP) >5 mg/L during Screening, or any rheumatic or autoimmune disease that requires systemic anti-inflammatory or immunomodulatory therapy.
  6. Subject has an acute illness within 14 days prior to Baseline.
  7. Subject has known or suspected intolerance or hypersensitivity to iron-containing products.
  8. Subject has a history of alcohol or substance abuse within the past year.
  9. Subject has a positive screen for cotinine or drugs of abuse.
  10. Subject is positive for HIV, hepatitis B, or hepatitis C.
  11. Subject uses tobacco in any form (e.g., smoking or chewing) or other nicotine-containing products in any form (e.g., gum, patch, etc.). Ex-users must report that they have stopped using tobacco for at least 30 days prior to Baseline.
  12. Subject donated blood or blood products (e.g., plasma or platelets) within 60 days prior to Baseline.
  13. Subject participated in an investigational drug study within 30 days prior to Baseline.
  14. Subject is pregnant or intends to become pregnant before completing the study.
  15. Subject's current medical status, in the investigator's opinion, would preclude participation in the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02636049


Locations
Layout table for location information
United States, Michigan
Jasper Clinic
Kalamazoo, Michigan, United States, 49007
Sponsors and Collaborators
Rockwell Medical Technologies, Inc.
Investigators
Layout table for investigator information
Study Director: Raymond D Pratt, MD FACP Rockwell Medical, Inc
Layout table for additonal information
Responsible Party: Rockwell Medical Technologies, Inc.
ClinicalTrials.gov Identifier: NCT02636049    
Other Study ID Numbers: RMFPC-12
First Posted: December 21, 2015    Key Record Dates
Results First Posted: February 1, 2019
Last Update Posted: August 20, 2019
Last Verified: August 2019
Keywords provided by Rockwell Medical Technologies, Inc.:
pharmacokinetics
healthy adult volunteer
Additional relevant MeSH terms:
Layout table for MeSH terms
Kidney Failure, Chronic
Kidney Diseases
Urologic Diseases
Renal Insufficiency, Chronic
Renal Insufficiency